Introduction: Diabetes mellitus (DM) is a metabolic disorder characterised by excessively high blood sugar levels and elevated oxidative stress, resulting in lipid, protein, and carbohydrate metabolism problems. Diabetes mellitus increases the risk of coronary artery disease, stroke, and other vascular problems considerably. Aim: Nebivolol has enhanced tolerability profile with respect to adverse effects usually allied with nonselective __ampersandsignbeta;-blockers so, the study__ampersandsignrsquo;s goal is to assess the comparative effects of nebivolol and metoprolol on metabolic parameters in type II diabetes mellitus with essential hypertension patients. Methodology: The subjects enrolled for this study are selected from the Out Patient Department of Medicine, MGM medical College, Aurangabad according to the inclusion and exclusion criteria. Written informed consent is obtained from each patient. Various biochemical parameters are assessed for comparative study of nebivolol and metoprolol drugs in patients. 3 month randomized open label study design is selected and 40 patients are divided into 2 groups, administered nebivolol and metoprolol in each group. Parameters like fasting blood glucose level, postprandial blood glucose level (BGL), HbA1c level, systolic and diastolic blood pressure are assessed using student paired and unpaired t-test. Result: Fasting blood glucose level, postprandial BGL, HbA1c and systolic blood pressure except diastolic blood pressure are found to be reduced significant in nebivolol treated group than compared to metoprolol group patients. Nebivolol doesn__ampersandsignrsquo;t show side effect of fatigue. Conclusion: This comparative study concluded that Nebivolol more efficacious than metoprolol in terms of reducing BGL, HbA1c and blood pressure along with lesser side effects in type II diabetic and hypertension patients.